Related Experiment Video
Updated: Jun 23, 2026

Injection of Hydrogel Biomaterial Scaffolds to The Brain After Stroke
Published on: October 1, 2020
Neuroprotection After Intracerebral Hemorrhage: Apoptosis, Neurogenesis, and Prospects of Stem Cell Therapy
Ziwei Wang1, Jing Tian2, Ying Kong3
1Second Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, 150000, Heilongjiang Province, China, hljucm.edu.cn.
Abstract:
This comprehensive review examines the interconnected roles of apoptosis, neurogenesis, and stem cell therapy in neuroprotection and neurorestoration following intracerebral hemorrhage (ICH). We emphasize that these processes should be interpreted within a unified secondary injury cascade rather than as independent topics. Following ICH, hematoma toxicity, erythrocyte lysis, iron overload, oxidative stress, inflammation, blood-brain barrier disruption, and perihematomal edema interact to activate multiple regulated cell death pathways. Apoptosis remains important, but ferroptosis and other inflammatory cell-death programs are also increasingly relevant to ICH research. The endogenous neurogenic response following ICH is analyzed, highlighting both its potential and its marked limitations in spontaneous recovery, particularly the poor survival and functional integration of newborn cells. We then examine how stem cell therapy may bridge antiapoptotic neuroprotection and proneurogenic neurorestoration through paracrine signaling, microenvironment modulation, and limited cell replacement. Current diagnostic advances and clinical trial designs for stem cell therapy in ICH are reviewed, but we also discuss major translational barriers, including weak distinction between rodent and human evidence, limited cell survival, delivery-route constraints, immune compatibility, source heterogeneity, and tumorigenicity. Finally, we propose that future progress will require stage-specific and clinically translatable strategies rather than isolated pathway targeting. This integrated framework may help refine therapeutic priorities for ICH patients.
